Immupharma Plc (LON:IMM) Chairman with Tim McCarthy talks with DirectorsTalk about the ongoing Phase III clinical trial of Lupuzor™. Tim talks about overall activity in the US, early traction in patient recruitment, confidence in recruiting the full 30 patients in Mauritius and key milestones over the rest of the year.
Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera, Harvard Healthcare and Expedeon Holdings. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing. A Fellow of the Association of Chartered Certified Accountants, Mr McCarthy has an MBA from Cranfield School of Management.
Immupharma Plc market strategy is to license our assets to leading international corporations that are well-placed to further develop and/or commercialise our drugs. Our corporate deal with Cephalon Inc. in 2008, for the worldwide rights of our lead drug candidate for the treatment of Lupus, Lupuzor™ is one example of this strategy in action. The company have a significant collaborative research and development agreement with the CNRS, which grants ImmuPharma worldwide exclusive rights to exploit commercially certain discoveries.
